Postgraduate Medicine
Volume 134, 2022 - Issue 1
Clinical Features - Commentary
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
Sean Whartona York University, McMaster University and Wharton Weight Management Clinic, Toronto, ON, CanadaCorrespondence[email protected]
https://orcid.org/0000-0003-0111-1530
https://orcid.org/0000-0003-0111-1530, Melanie Daviesb Diabetes Research Centre, University of Leicester, Leicester, UK;c NIHR Leicester Biomedical Research Centre, Leicester, UKhttps://orcid.org/0000-0002-9987-9371
https://orcid.org/0000-0002-9987-9371, Dror Dickerd Internal Medicine Department & Obesity Clinic, Hasharon Hospital-Rabin Medical Center, Petach-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israelhttps://orcid.org/0000-0001-8546-6245
https://orcid.org/0000-0001-8546-6245, Ildiko Lingvaye Departments of Internal Medicine/Endocrinology and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USAhttps://orcid.org/0000-0001-7006-7401
https://orcid.org/0000-0001-7006-7401, Ofri Mosenzonf DiabetesUnit, Department of Endocrinology and Metabolism, Hadassah Medical Center; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israelhttps://orcid.org/0000-0002-5702-7584
https://orcid.org/0000-0002-5702-7584, Domenica M. Rubinog Washington Center for Weight Management and Research, Arlington, VA, USAhttps://orcid.org/0000-0002-3072-2819
https://orcid.org/0000-0002-3072-2819 & Sue D. Pedersenh C-ENDO Diabetes & Endocrinology Clinic Calgary, Calgary, AB, Canadahttps://orcid.org/0000-0002-4355-1764
https://orcid.org/0000-0002-4355-1764 show all